Zerigo Health, a US-based developer of treatments for chronic skin conditions, has secured $43m in a series B round featuring corporates Bayer, Cigna and Leverage Health Solutions.
The round was led by healthcare venture capital fund 7wireVentures and included General Catalyst, Dragoneer, SV Health Investors, HIG Capital and Bluestem Capital.
Leverage Health Solutions invested directly while fellow health services provider Cigna did so through its Cigna Ventures unit and pharmaceutical and chemicals producer Bayer took part through subsidiary Leaps by Bayer.
Zerigo has created a system which uses narrowband ultraviolet B phototherapy to remotely treat chronic skin conditions in addition to offering patients personalised support.
Glen Tullman, managing partner of 7wireVentures, will take a board seat at Zerigo in connection with the round, which lifted its equity funding to approximately $67m since it was founded in 2014 as Skylit Medical.
The company closed a $2m seed round in April 2016 that included Serra Ventures, adding $3.6m from undisclosed investors in December the same year. It received $1m in debt financing from unnamed backers in 2018, according to a securities filing.
HIG BioHealth Partners, 7wire Ventures, SV Health Investors and Bluestem Capital supplied a further $18m for Zerigo in the form of an October 2019 series A round.
